Amicus Therapeutics (NASDAQ:FOLD – Get Free Report) and Protagonist Therapeutics (NASDAQ:PTGX – Get Free Report) are both mid-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, risk, earnings, dividends, valuation, profitability and analyst recommendations.
Profitability
This table compares Amicus Therapeutics and Protagonist Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Amicus Therapeutics | -10.62% | 12.44% | 2.60% |
| Protagonist Therapeutics | 52.76% | 34.68% | 30.98% |
Analyst Recommendations
This is a summary of current ratings and recommmendations for Amicus Therapeutics and Protagonist Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Amicus Therapeutics | 0 | 2 | 7 | 0 | 2.78 |
| Protagonist Therapeutics | 0 | 1 | 7 | 1 | 3.00 |
Valuation & Earnings
This table compares Amicus Therapeutics and Protagonist Therapeutics”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Amicus Therapeutics | $528.30 million | 5.31 | -$151.58 million | ($0.18) | -50.75 |
| Protagonist Therapeutics | $434.43 million | 5.43 | -$78.96 million | $4.20 | 9.15 |
Protagonist Therapeutics has lower revenue, but higher earnings than Amicus Therapeutics. Amicus Therapeutics is trading at a lower price-to-earnings ratio than Protagonist Therapeutics, indicating that it is currently the more affordable of the two stocks.
Insider & Institutional Ownership
98.6% of Protagonist Therapeutics shares are held by institutional investors. 2.2% of Amicus Therapeutics shares are held by insiders. Comparatively, 5.4% of Protagonist Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Volatility and Risk
Amicus Therapeutics has a beta of 0.61, indicating that its share price is 39% less volatile than the S&P 500. Comparatively, Protagonist Therapeutics has a beta of 2.34, indicating that its share price is 134% more volatile than the S&P 500.
Summary
Protagonist Therapeutics beats Amicus Therapeutics on 12 of the 14 factors compared between the two stocks.
About Amicus Therapeutics
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.
About Protagonist Therapeutics
Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
